Loading…
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-22M | $-22M | $-19M | -280.5% | - | -18.5% |
| 2024 | $0M | $-27M | $-27M | $-22M | -26189.1% | - | 10.3% |
| 2023 | $0M | $-25M | $-25M | $-22M | 24.8% | - | 22.7% |
| 2022 | $0M | $-20M | $-20M | $-18M | 26.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 20.21 | 24.97 | 25.16 | 22.50 |
| Research And Development | 16.39 | 21.71 | 18.68 | 10.29 |
| Selling General And Administration | 3.82 | 3.27 | 6.48 | 12.20 |
| Total Expenses | 20.21 | 24.97 | 25.16 | 22.50 |
| Operating Income | -20.21 | -24.97 | -25.16 | -22.50 |
| Total Operating Income As Reported | -20.21 | -24.97 | -25.16 | -22.50 |
| EBITDA | -20.14 | -24.70 | -27.27 | -22.21 |
| Normalized EBITDA | -20.18 | -24.62 | -27.53 | -22.21 |
| EBIT | -20.14 | -24.70 | -27.27 | -22.21 |
| Interest Income | 0.03 | 0.35 | 0.22 | 0.29 |
| Interest Expense | 0.02 | 0.04 | 0.02 | 0.02 |
| Net Interest Income | 0.01 | 0.31 | 0.20 | 0.27 |
| Other Non Operating Income Expenses | - | - | -2.59 | - |
| Other Income Expense | 0.04 | -0.08 | -2.33 | - |
| Interest Income Non Operating | 0.03 | 0.35 | 0.22 | 0.29 |
| Interest Expense Non Operating | 0.02 | 0.04 | 0.02 | 0.02 |
| Net Non Operating Interest Income Expense | 0.01 | 0.31 | 0.20 | 0.27 |
| Pretax Income | -20.16 | -24.74 | -27.29 | -22.23 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -20.16 | -24.74 | -27.29 | -22.23 |
| Net Income From Continuing And Discontinued Operation | -20.16 | -24.74 | -27.29 | -22.23 |
| Net Income From Continuing Operation Net Minority Interest | -20.16 | -24.74 | -27.29 | -22.23 |
| Net Income | -20.16 | -24.74 | -27.29 | -22.23 |
| Net Income Common Stockholders | -20.16 | -24.74 | -27.29 | -22.23 |
| Net Income Including Noncontrolling Interests | -20.16 | -24.74 | -27.29 | -22.23 |
| Normalized Income | -20.20 | -24.66 | -27.55 | -22.23 |
| Diluted NI Availto Com Stockholders | -20.16 | -24.74 | -27.29 | -22.23 |
| Basic Average Shares | 15.03 | 19.11 | 8.37 | - |
| Diluted Average Shares | 15.03 | 19.11 | 8.37 | - |
| Total Unusual Items | 0.04 | -0.08 | 0.26 | - |
| Total Unusual Items Excluding Goodwill | 0.04 | -0.08 | 0.26 | - |
| Gain On Sale Of Security | 0.04 | -0.08 | 0.26 | - |
| General And Administrative Expense | 3.82 | 3.27 | 6.48 | 12.20 |
| Other Gand A | 1.24 | 1.44 | 2.71 | 4.60 |
| Salaries And Wages | 2.58 | 1.83 | 3.77 | 7.61 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Actuate Therapeutics, Inc. Common stockthis co. | ACTU | $46M | -2.09 | 5.86 | -280.5% | - |
| DocGo Inc. | DCGO | $56M | -0.31 | 0.39 | -126.7% | -0.47 |
| aTyr Pharma, Inc. | ATYR | $50M | -0.68 | 0.75 | -109.8% | -0.68 |
| Myomo, Inc. | MYO | $50M | -3.20 | 4.37 | -136.6% | -4.36 |
| Accuray Incorporated | ARAY | $43M |
| -27.33 |
| 0.54 |
| -2.0% |
| 8.03 |
| Gossamer Bio, Inc. | GOSS | $42M | -0.24 | -0.34 | 138.8% | -1.31 |
| Tevogen Bio Holdings Inc. | TVGN | $41M | -1.57 | -2.42 | 154.2% | -1.89 |
| INmune Bio Inc. | INMB | $36M | -0.78 | 1.53 | -195.3% | -0.40 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | -1.59 | 1.38 | -87.0% | -0.31 |
| Peer Median | - | -1.18 | 0.64 | -98.4% | -0.57 | |